Immunotherapy is considered to be the fourth pillar of cancer treatment (in parallel with surgery, radiotherapy, and chemotherapy), by enhancing the ability of the immune system to target and kill tumor cells, including: 1) Blocking antibodies to the inhibitory immune checkpoint pathway 2) Cell therapy based on dendritic cells… Continue Reading Nature: The next step in cancer immunotherapy is joint therapy. Eradication of cancer is not the ultimate goal.
Drug: CAR-T therapy Magazine: Nature Highlights: A clever design that increases the anti-cancer ability of CAR-T therapy More and more cancer patients are being treated with CAR-T cell therapy. CAR, the English full name of Chimeric Antigen Receptor, chimeric antigen receptor, is a kind of “navigation” that… Continue Reading Upgraded version of CAR-T therapy, greatly improved anti-cancer ability
Human immunodeficiency virus (HIV) is a retrovirus that infects cells of the human immune system, destroying or damaging its function. There is no symptom at the beginning of HIV infection, but as the infection progresses, the immune system begins to weaken. The final stage of infection is the acquired… Continue Reading Can immunotherapy create a miracle to cure AIDS?
Cellular therapies based on effector T cells over the past decade, particularly CAR-T therapy, have revolutionized the treatment of many types of cancer. In 2017, the FDA approved two CAR-T therapies for the treatment of certain types of cancer associated with B cells, and research in the field of… Continue Reading How to apply CAR-T therapy to treat autoimmune diseases?
Since August 2017, the FDA has approved a total of four therapeutic drugs that are different from traditional small molecule drugs and macromolecular drugs. They are Novartis CAR-T drugs Kymriah (tisagenlecleucel-T) and Gilead (Kite). CAR-T drug Yescarta (axicabtagene ciloleucel), Spark gene therapy drug Luxturna (voretigene neparvovec-rzyl) and small interfering… Continue Reading The layout of global TOP10 pharmaceutical companies in the CAR-T field
The future of rindopepimut seems to be bright in 2015. The results of three clinical trials have shown that this peptide tumor therapeutic vaccine can elicit an immune response and delay polymorphic glioblastoma multiforme (GBM). The disease progression of the patient. GBM is the most malignant brain cancer. The… Continue Reading Bronze Age of Glioblastoma Immunotherapy
Clinical outcomes are one of the gold standards for assessing the availability of new drugs, which often determines their reputation after listing. As a “living drug”, CAR-T therapy is to collect blood from patients, transport blood samples to the production GMP center, extract and purify T cells, lentivirus transfection… Continue Reading CAR-T production, outsourcing or building your own factory?
T cells have always been at the center of tumor immunotherapy. In recent years, CAR-T therapy has shown its power to treat certain types of cancer, and the FDA has approved two CAR-T therapies for the treatment of lymphoma or leukemia. At the same time, there are currently hundreds… Continue Reading How will CAR-NK therapy affect the progress of cell therapy?
For some B-cell-related blood cancers, the efficacy of CAR-T therapy is unquestionable. Last year, the FDA approved two CAR-T therapies, and many pharmaceutical companies began investing a lot of money and manpower in the field. However, the clinical application of CAR-T therapy still faces many obstacles, such as toxicity… Continue Reading New directions for CAR-T treatment: autoimmune disease and graft versus host disease
Busy week for BCMA. On Monday, the FDA granted Gilead/Kite a CATMA-recognized CAR-T therapy orphan drug. At the same time, at the myeloma 2018 meeting, Amgen also announced early clinical data on its TBMA-targeted BiTE drug AMG-420. Affected by the data, the shares of Bluebird Bio and Celgene fell on… Continue Reading CAR-T confronts double antibodies, and Amgen’s drugs targeting BCMA may be a huge threat to Bluebird